517 related articles for article (PubMed ID: 16492205)
1. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
2. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Linnebjerg H; Park S; Kothare PA; Trautmann ME; Mace K; Fineman M; Wilding I; Nauck M; Horowitz M
Regul Pept; 2008 Nov; 151(1-3):123-9. PubMed ID: 18675854
[TBL] [Abstract][Full Text] [Related]
3. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
4. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
[TBL] [Abstract][Full Text] [Related]
6. Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers.
Pinelli NR; Jantz A; Smith Z; Abouhassan A; Ayar C; Jaber NA; Clarke AW; Commissaris RL; Jaber LA
J Clin Pharmacol; 2011 Feb; 51(2):165-72. PubMed ID: 20484613
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.
Blase E; Taylor K; Gao HY; Wintle M; Fineman M
J Clin Pharmacol; 2005 May; 45(5):570-7. PubMed ID: 15831781
[TBL] [Abstract][Full Text] [Related]
9. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
[TBL] [Abstract][Full Text] [Related]
11. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
12. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
13. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
[TBL] [Abstract][Full Text] [Related]
14. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
[TBL] [Abstract][Full Text] [Related]
16. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
[TBL] [Abstract][Full Text] [Related]
17. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study.
Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
Diabetes Metab Res Rev; 2004; 20(6):472-8. PubMed ID: 15386822
[TBL] [Abstract][Full Text] [Related]
18. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
Fineman MS; Shen LZ; Taylor K; Kim DD; Baron AD
Diabetes Metab Res Rev; 2004; 20(5):411-7. PubMed ID: 15343588
[TBL] [Abstract][Full Text] [Related]
20. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
